The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts
Open accessAbstract
The October 2020 Global TB report reviews TB control strategies and United Nations (UN) targets set in the political declaration at the September 2018 UN General Assembly high-level meeting on TB held in New York. Progress in TB care and prevention has been very slow. In 2019, TB remained the most common cause of death from a single infectious pathogen. Globally, an estimated 10.0 million people developed TB disease in 2019, and there were an estimated 1.2 million TB deaths among HIV-negative people and an additional 208, 000 deaths among people living with HIV. Adults accounted for 88% and children for 12% of people with TB. The WHO regions of South-East Asia (44%), Africa (25%), and the Western Pacific (18%) had the most people with TB. Eight countries accounted for two thirds of the global total: India (26%), Indonesia (8.5%), China (8.4%), the Philippines (6.0%), Pakistan (5.7%), Nigeria (4.4%), Bangladesh (3.6%) and South Africa (3.6%). Only 30% of the 3.5 million five-year target for children treated for TB was met. Major advances have been development of new all oral regimens for MDRTB and new regimens for preventive therapy. In 2020, the COVID-19 pandemic dislodged TB from the top infectious disease cause of mortality globally. Notably, global TB control efforts were not on track even before the advent of the COVID-19 pandemic. Many challenges remain to improve sub-optimal TB treatment and prevention services. Tuberculosis screening and diagnostic test services need to be ramped up. The major drivers of TB remain undernutrition, poverty, diabetes, tobacco smoking, and household air pollution and these need be addressed to achieve the WHO 2035 TB care and prevention targets. National programs need to include interventions for post-tuberculosis holistic wellbeing. From first detection of COVID-19 global coordination and political will with huge financial investments have led to the development of effective vaccines against SARS-CoV2 infection. The world now needs to similarly focus on development of new vaccines for TB utilizing new technological methods.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global tuberculosis report (2014)
Gabbasova, L. A., & Who, E. R. E. (2014) · Cited by 12,702
The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling
Houben, R. M. G. J., & Dodd, P. J. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002152 · Cited by 2,054 · cited 1×
“…that by 2030 and 2050, this pool of latently infected ersons will generate 16.3 and 8.3 people with active TB per 00,000 population respectively (Houben and Dodd, 2016). owever, with current and hopefully future diagnostic and reatment tools most if not all these episodes of TB can be revented.”
BackgroundInfluentialThree Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection
Sterling, T. R., Villarino, M. E., Borisov, A. S., Shang, N., Gordin, F., Bliven-Sizemore, E., Hackman, J., Hamilton, C. D., Menzies, D., Kerrigan, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104875 · Cited by 977
Tuberculosis and diabetes mellitus: convergence of two epidemics
Dooley, K. E., & Chaisson, R. E. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70282-8 · Cited by 932
COVID-19 vaccines: where we stand and challenges ahead
on behalf of the COVID-19 Commission of Accademia Nazionale dei Lincei, R., Forni, G., & Mantovani, A. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00720-9 · Cited by 763
Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline
Diacon, A. H., Pym, A., Grobusch, M. P., de los Rios, J. M., Gotuzzo, E., Vasilyeva, I., Leimane, V., Andries, K., Bakare, N., De Marez, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313865 · Cited by 746
Directly observed therapy for treating tuberculosis
Karumbi, J., & Garner, P. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003343.pub4 · Cited by 644
Alipanah, N., Jarlsberg, L., Miller, C., Linh, N. N., Falzon, D., Jaramillo, E., & Nahid, P. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002595 · Cited by 503 · cited 1×
“An approach that is based on providing omprehensive and individualized support to people being treated or TB is more likely to be acceptable to people with TB and their amilies and has been associated with better treatment completion ates (Alipanah et al., 2018).”
BackgroundLee, K. K., Bing, R., Kiang, J., Bashir, S., Spath, N., Stelzle, D., Mortimer, K., Bularga, A., Doudesis, D., Joshi, S. S., et al. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30343-0 · Cited by 484
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis
Nunn, A. J., Phillips, P. P. J., Meredith, S. K., Chiang, C.-Y., Conradie, F., Dalai, D., van Deun, A., Dat, P.-T., Lan, N., Master, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811867 · Cited by 390
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis
Swindells, S., Ramchandani, R., Gupta, A., Benson, C. A., Leon-Cruz, J., Mwelase, N., Jean Juste, M. A., Lama, J. R., Valencia, J., Omoz-Oarhe, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806808 · Cited by 363
Building a tuberculosis-free world: The Lancet Commission on tuberculosis
Reid, M. J. A., Arinaminpathy, N., Bloom, A., Bloom, B. R., Boehme, C., Chaisson, R., Chin, D. P., Churchyard, G., Cox, H., Ditiu, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30024-8 · Cited by 361
Romanowski, K., Baumann, B., Basham, C. A., Ahmad Khan, F., Fox, G. J., & Johnston, J. C. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30309-3 · Cited by 288
Post-tuberculosis lung health: perspectives from the First International Symposium
Allwood, B. W., van der Zalm, M. M., Amaral, A. F. S., Byrne, A., Datta, S., Egere, U., Evans, C. A., Evans, D., Gray, D. M., Hoddinott, G., et al. (2020) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.20.0067 · Cited by 270
Corbett, E. L., Bandason, T., Duong, T., Dauya, E., Makamure, B., Churchyard, G. J., Williams, B. G., Munyati, S. S., Butterworth, A. E., Mason, P. R., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61425-0 · Cited by 247
Community-wide Screening for Tuberculosis in a High-Prevalence Setting
Marks, G. B., Nguyen, N. V., Nguyen, P. T. B., Nguyen, T.-A., Nguyen, H. B., Tran, K. H., Nguyen, S. V., Luu, K. B., Tran, D. T. T., Vo, Q. T. N., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902129 · Cited by 230
Noubiap, J. J., Nansseu, J. R., Nyaga, U. F., Nkeck, J. R., Endomba, F. T., Kaze, A. D., Agbor, V. N., & Bigna, J. J. (2019) · The Lancet Global Health · doi:10.1016/s2214-109x(18)30487-x · Cited by 218
Subbaraman, R., Nathavitharana, R. R., Mayer, K. H., Satyanarayana, S., Chadha, V. K., Arinaminpathy, N., & Pai, M. (2019) · PLOS Medicine · doi:10.1371/journal.pmed.1002754 · Cited by 211
Directly observed therapy for treating tuberculosis
Volmink, J. A., & Garner, P. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003343.pub3 · Cited by 177
The impact of digital health technologies on tuberculosis treatment: a systematic review
Ngwatu, B. K., Nsengiyumva, N. P., Oxlade, O., Mappin-Kasirer, B., Nguyen, N. L., Jaramillo, E., Falzon, D., & Schwartzman, K. (2018) · European Respiratory Journal · doi:10.1183/13993003.01596-2017 · Cited by 174
Extensive Drug Resistance Acquired During Treatment of Multidrug-Resistant Tuberculosis
Cegielski, J. P., Dalton, T. L., Yagui, M., Wattanaamornkiet, W., Volchenkov, G. V., Via, L. E., der Walt, M. L. V., Tupasi, T. E., Smith, S. E., Odendaal, R., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu572 · Cited by 161
Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries
Trébucq, A., Schwoebel, V., Kashongwe, Z. M., Bakayoko, A. S., Kuaban, C., Noeske, J., Hassane-Harouna, S., Souleymane, B., Piubello, A., Ciza, F., et al. (2017) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.17.0498 · Cited by 156
Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis
Angeline Grace, G., Mittal, A., Jain, S., Tripathy, J. P., Satyanarayana, S., Tharyan, P., & Kirubakaran, R. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012918.pub2 · Cited by 89
Chakaya, J. M., Kirenga, B., & Getahun, H. (2016) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2016.03.001 · Cited by 65
Self-citationThe long shadow post-tuberculosis
Allwood, B., van der Zalm, M. M., Makanda, G., Mortimer, K. J., Amaral, A. F. S., Uzochukwu, E., Denise, E., Gray, D. M., Hoddinott, G., Olena, I., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30564-x · Cited by 65
Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis
Angeline Grace, G., Mittal, A., Jain, S., Tripathy, J. P., Satyanarayana, S., Tharyan, P., & Kirubakaran, R. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012918 · Cited by 48
García‐Basteiro, A. L., Brew, J., Williams, B. G., Borgdorff, M. W., & Cobelens, F. G. J. (2018) · International Journal of Epidemiology · doi:10.1093/ije/dyy144 · Cited by 42
Bulabula, A. N. H., Nelson, J. A., Musafiri, E. M., Machekano, R. N., Sam-Agudu, N. A., Diacon, A. H., Shah, M., Creswell, J., Theron, G., Warren, R. M., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1105 · Cited by 27
Self-citationBisimwa, B. C., Nachega, J. B., Warren, R. M., Theron, G., Metcalfe, J. Z., Shah, M., Diacon, A. H., Sam-Agudu, N. A., Yotebieng, M., Bulabula, A. N. H., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa873 · Cited by 22
Self-citationSumner, T., Scriba, T. J., Penn‐Nicholson, A., Hatherill, M., & White, R. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-47645-z · Cited by 16
Estimation of subnational tuberculosis burden: generation and application of a new tool in Indonesia
Parwati, C. G., Farid, M. N., Nasution, H. S., Sulistyo, Basri, C., Lolong, D. B., Gebhard, A. C., Tiemersma, E. W., Pambudi, I., Surya, A., et al. (2020) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.19.0139 · Cited by 14
Research works printed but not linked: 5
- Cox, 2018, Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis, Int J Tuberc Lung Dis, 22, 407, 10.5588/ijtld.17.0706 · doi:10.5588/ijtld.17.0706
- Gler, 2012, Delamanid for multidrug-resistant pulmonary tuberculosis, N Engl J Med, 366, 2151, 10.1056/NEJMoa1112433 · doi:10.1056/nejmoa1112433
- Kaplan, 1972, Tuberculosis in Alaska, 1970. The continued decline of the tuberculosis epidemic, Am Rev Respir Dis, 105, 920
- Trébucq, 2016, Numbers of tuberculosis cases: Dreams and reality, Int J Tuberc Lung Dis, 20, 1288, 10.5588/ijtld.15.0873 · doi:10.5588/ijtld.15.0873
- Zumla, 2020, COVID-19 and tuberculosis-threats and opportunities, Int J Tuberc Lung Dis, 24, 757, 10.5588/ijtld.20.0387 · doi:10.5588/ijtld.20.0387
Cited by
Zhuang, X., Li, L., Liu, T., Zhang, R., Yang, P., Wang, X., & Dai, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1037814 · Cited by 88
Kim, Y., Park, J. Y., Hwang, E. J., Lee, S. M., & Park, C. M. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1342 · Cited by 31
“Major thoracic diseases such as lung cancer and tuberculosis are among the leading causes of death worldwide (28,29), and numerous radiologic studies have been performed to diagnose them.”
BackgroundMungai, B., Ong‘angò, J., Ku, C. C., Henrion, M. Y. R., Morton, B., Joekes, E., Onyango, E., Kiplimo, R., Kirathe, D., Masini, E., et al. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001272 · Cited by 24
“With over 95% tuberculosis (TB) cases and deaths occurring in developing countries, there is need for substantially improved case detection to find the “missing millions” and accelerate action to achieve the sustainable development goals to end TB by 2030 [1–4].”
Zarin, S., Shariq, M., Rastogi, N., Ahuja, Y., Manjunath, P., Alam, A., Hasnain, S. E., & Ehtesham, N. Z. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05200-8 · Cited by 13
Self-citationEmam, E. A. F., Roy, K., Singh, D. P., Saini, D. K., & Varshney, U. (2025) · Journal of Bacteriology · doi:10.1128/jb.00314-24 · Cited by 5
Metadata
- Authors
- Chakaya, J., Khan, M., Ntoumi, F., Aklillu, E., Fatima, R., Mwaba, P., Kapata, N., Mfinanga, S., Hasnain, S. E., Katoto, P. D. M. C., Bulabula, A. N. H., Sam-Agudu, N. A., Nachega, J. B., Tiberi, S., McHugh, T. D., Abubakar, I., & Zumla, A.
- Venue
- International Journal of Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 113
- Pages
- S7-S12
- ISSN
- 1201-9712 (ISSN-L)
- OpenAlex
- W3135682442
- Cited by
- 1,104
- References
- 31
- FWCI
- 61.82
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.